Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.
The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.
RU58841 mixed with Minoxidil seems less effective over time, so the user plans to switch to a PG and Ethanol dilution for better results. They also consider using rosemary oil with Minoxidil to enhance RU58841 absorption.
PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.
The conversation is about starting a Discord group for people using KX-826 as their only treatment for hair loss, excluding those who are not serious or use multiple treatments. Someone agrees with the idea but mentions "GP :3," which is unclear.
The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.
Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.
Minoxidil is commonly used for male pattern baldness, but Procapil is considered to have fewer side effects and be more effective. The user seeks information or experiences regarding Procapil.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
The user successfully improved their hair from Norwood 3 to 0.5 using finasteride, topical minoxidil, microneedling, and a hair peptide, and plans to maintain it with dutasteride. They are leaving the forum due to emotional distress caused by the community.
OP mixed RU58841 with minoxidil and initially saw crystals, but realized they were bubbles. They asked for advice on application frequency for a 5% solution.
The user shared progress on hair regrowth after using 5% Minoxidil twice daily and microneedling 0.5mm a few times a week for 47 days. Other users noted visible improvement and regrowth of baby hair in the frontal temporal region.
User "hairlossblows" shares their positive experience with minoxidil, microneedling, and finasteride for hair loss treatment. They report significant hair regrowth, especially in the hairline, and minimal side effects from finasteride.
User plans to switch from oral to .005% topical finasteride, using a solvent from minoxidilmax and later Essengen-F. They will monitor DHT levels and seek advice on solvents and sleep caps.
Lactobacillus reuteri 6475 is being used by a person who reports healthier hair after one month, despite initial shedding. The discussion includes speculation about its effects on gut bacteria and scalp inflammation.
A user discusses a dermatologist-prescribed topical solution for hair loss containing 7% Minoxidil, 0.0125% Tretinoin, and 0.1% Dutasteride, questioning its safety. Responses suggest the concentration is generally safe, though there is skepticism about daily use at high concentrations, and similar products like HairStim and Happy Head are mentioned.
A 28-year-old male reported significant hair regrowth using 5mg minoxidil and 0.5mg dutasteride over five months, with occasional ketoconazole use. Users discussed side effects like stuffy nose and low libido, and shared experiences with different hair loss treatments.
A user experienced increased shedding after adding KX-826 to their long-term finasteride and minoxidil regimen. Another user reported mild side effects from KX-826, such as stomach and testicle pain.
User "al_ick" shares progress with topical fin, min, tret, and micro needling for hair loss, showing good results. They use hims fin and min combination spray, applying 5-7 sprays for better coverage.
The conversation is about a person's 6-week progress using 2.5 mg oral minoxidil, 0.5 mg dutasteride, weekly derma stamping at 1.5 mm, and rosemary oil for hair loss, with some initial shedding but no side effects. They are optimistic about future results.
The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.
The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.
The conversation humorously discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It highlights a funny brand name found on Amazon related to derma stamps.
PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.
Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.
The user documented eight weeks of progress using 5% topical minoxidil, 1 mg oral finasteride, and weekly microneedling. They reported diffuse fill-in and new baby hairs, with plans to taper off topical minoxidil.
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.
The user experienced increased hair miniaturization and shedding despite using finasteride, topical minoxidil, microneedling, and other treatments. They are considering more aggressive treatments or a hair system if no improvement occurs by the end of 2025.